FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2117348043> ?p ?o ?g. }

• W2117348043 endingPage "1631" @default.
• W2117348043 startingPage "1618" @default.
• W2117348043 abstract "// Catia Giovannini 1,2 , Michele Baglioni 1,2 , Marco Baron Toaldo 3 , Cristiano Ventrucci 1 , Stefania D’Adamo 1 , Mario Cipone 3 , Pasquale Chieco 1 , Laura Gramantieri 1,* and Luigi Bolondi 1,2,* . 1 Center for Applied Biomedical Research (CRBA), S.Orsola-Malpighi University Hospital, Bologna, Italy; 2 Department of Clinical Medicine University of Bologna, Bologna, Italy; 3 Department of Veterinary Medical Science University of Bologna, Bologna, Italy. * Contributed equally to this work. Correspondence: C Giovannini, email: // Keywords : ERK, drug resistance, angiogenesis, cell proliferation, Notch3 Received : July 30, 2013 Accepted : August 22, 2013 Published : August 24, 2013 Abstract Sorafenib (Nexavar), a multiple kinase inhibitor, is the only clinically approved drug for patients with advanced HCC. However, its therapeutic success is limited by the emergence of drug resistance. Here we found that p21 and pGSK3β Ser9 are major players in the resistance to sorafenib. We recently reported that aberrant Notch3 expression in HCC contributes to doxorubicin resistance in vitro and, therefore, we focused on the mechanisms that associate Notch3 to acquired drug resistance. In this study we first found that Notch3 inhibition significantly increased the apoptosis inducing effect of sorafenib in HCC cells via specific down-regulation of p21 and up-regulation of pGSK3β Ser9 . Using a mouse xenograft model we further found that Notch3 depletion combined with 21 days of sorafenib treatment exerts a substantial antitumor effect in vivo . Interestingly, we showed that, upon exposure to sorafenib treatment, Notch3 depleted xenografts maintain lower levels of p21 and higher levels of pGSK3β Ser9 than control xenografts. Thus, this study demonstrated that inhibition of Notch3 signaling prevents HCC-mediate drug resistance and sensitizes HCC cells to sorafenib. Finally, we validated our in vitro and in vivo results in primary human HCCs showing that Notch3 protein expression positively correlated with p21 protein expression and negatively correlated with pGSK3β Ser9 expression. In conclusion, the results presented in this study demonstrated that Notch3 silencing enhances the effect of sorafenib by overcoming drug resistance. Notch3 inhibition in combination with sorafenib can be a promising strategy for treatment of HCC." @default.
• W2117348043 created "2016-06-24" @default.
• W2117348043 creator A5005639704 @default.
• W2117348043 creator A5032016003 @default.
• W2117348043 creator A5033469250 @default.
• W2117348043 creator A5036820714 @default.
• W2117348043 creator A5037793919 @default.
• W2117348043 creator A5045056758 @default.
• W2117348043 creator A5047213013 @default.
• W2117348043 creator A5068348071 @default.
• W2117348043 creator A5085011734 @default.
• W2117348043 date "2013-08-24" @default.
• W2117348043 modified "2023-10-09" @default.
• W2117348043 title "Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3β phosphorylation and p21 down-regulation in hepatocellular carcinoma" @default.
• W2117348043 cites W1963483543 @default.
• W2117348043 cites W1971837077 @default.
• W2117348043 cites W1974342793 @default.
• W2117348043 cites W1974567048 @default.
• W2117348043 cites W1992360356 @default.
• W2117348043 cites W1994193851 @default.
• W2117348043 cites W2012116432 @default.
• W2117348043 cites W2012393060 @default.
• W2117348043 cites W2018305254 @default.
• W2117348043 cites W2020485312 @default.
• W2117348043 cites W2046623913 @default.
• W2117348043 cites W2047674690 @default.
• W2117348043 cites W2050311403 @default.
• W2117348043 cites W2055229514 @default.
• W2117348043 cites W2063558612 @default.
• W2117348043 cites W2076892771 @default.
• W2117348043 cites W2085682228 @default.
• W2117348043 cites W2124323423 @default.
• W2117348043 cites W2127125400 @default.
• W2117348043 cites W2129124160 @default.
• W2117348043 cites W2133176657 @default.
• W2117348043 cites W2140765540 @default.
• W2117348043 cites W2150799704 @default.
• W2117348043 cites W2151898419 @default.
• W2117348043 cites W2152993806 @default.
• W2117348043 cites W2157540307 @default.
• W2117348043 cites W2157905883 @default.
• W2117348043 cites W2168439880 @default.
• W2117348043 cites W4213058179 @default.
• W2117348043 doi "https://doi.org/10.18632/oncotarget.1221" @default.
• W2117348043 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3858550" @default.
• W2117348043 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24113128" @default.
• W2117348043 hasPublicationYear "2013" @default.
• W2117348043 type Work @default.
• W2117348043 sameAs 2117348043 @default.
• W2117348043 citedByCount "41" @default.
• W2117348043 countsByYear W21173480432014 @default.
• W2117348043 countsByYear W21173480432015 @default.
• W2117348043 countsByYear W21173480432016 @default.
• W2117348043 countsByYear W21173480432017 @default.
• W2117348043 countsByYear W21173480432018 @default.
• W2117348043 countsByYear W21173480432019 @default.
• W2117348043 countsByYear W21173480432020 @default.
• W2117348043 countsByYear W21173480432021 @default.
• W2117348043 countsByYear W21173480432022 @default.
• W2117348043 countsByYear W21173480432023 @default.
• W2117348043 crossrefType "journal-article" @default.
• W2117348043 hasAuthorship W2117348043A5005639704 @default.
• W2117348043 hasAuthorship W2117348043A5032016003 @default.
• W2117348043 hasAuthorship W2117348043A5033469250 @default.
• W2117348043 hasAuthorship W2117348043A5036820714 @default.
• W2117348043 hasAuthorship W2117348043A5037793919 @default.
• W2117348043 hasAuthorship W2117348043A5045056758 @default.
• W2117348043 hasAuthorship W2117348043A5047213013 @default.
• W2117348043 hasAuthorship W2117348043A5068348071 @default.
• W2117348043 hasAuthorship W2117348043A5085011734 @default.
• W2117348043 hasBestOaLocation W21173480431 @default.
• W2117348043 hasConcept C114851261 @default.
• W2117348043 hasConcept C126322002 @default.
• W2117348043 hasConcept C143998085 @default.
• W2117348043 hasConcept C150903083 @default.
• W2117348043 hasConcept C184235292 @default.
• W2117348043 hasConcept C190283241 @default.
• W2117348043 hasConcept C207001950 @default.
• W2117348043 hasConcept C2778019345 @default.
• W2117348043 hasConcept C2778695046 @default.
• W2117348043 hasConcept C2780394083 @default.
• W2117348043 hasConcept C502942594 @default.
• W2117348043 hasConcept C55493867 @default.
• W2117348043 hasConcept C57074206 @default.
• W2117348043 hasConcept C71924100 @default.
• W2117348043 hasConcept C86803240 @default.
• W2117348043 hasConcept C89423630 @default.
• W2117348043 hasConcept C95444343 @default.
• W2117348043 hasConcept C98274493 @default.
• W2117348043 hasConceptScore W2117348043C114851261 @default.
• W2117348043 hasConceptScore W2117348043C126322002 @default.
• W2117348043 hasConceptScore W2117348043C143998085 @default.
• W2117348043 hasConceptScore W2117348043C150903083 @default.
• W2117348043 hasConceptScore W2117348043C184235292 @default.
• W2117348043 hasConceptScore W2117348043C190283241 @default.
• W2117348043 hasConceptScore W2117348043C207001950 @default.
• W2117348043 hasConceptScore W2117348043C2778019345 @default.
• W2117348043 hasConceptScore W2117348043C2778695046 @default.

• next